Marksans Pharma (NSE:MARKSANS) filed the transcript of its Q1 FY27 analyst and investor conference call on 20 August 2026, pursuant to SEBI Listing Regulations. The call, held on 13 August 2026, disclosed consolidated operating revenue of INR840.8 crores and record quarterly EBITDA and PAT figures.
Key Highlights
- Consolidated operating revenue for Q1 FY27 stood at INR840.8 crores, up 35.6% year-on-year from INR620 crores in Q1 FY26.
- EBITDA reached a record INR213 crores, representing 112.8% year-on-year growth, with EBITDA margin expanding 919 basis points to 25.3%.
- Profit after tax rose 173.9% year-on-year to INR159.4 crores, with cash balance crossing INR1,000 crores for the first time, ending the quarter at INR1,058 crores.
- UK and Europe delivered record quarterly revenue of INR356 crores, up 74.7% year-on-year, supported by the consolidation of QliniQ B.V., Netherlands, from 1 April 2026.
About the Company
Marksans Pharma (NSE:MARKSANS), headquartered in Mumbai, is a pharmaceutical manufacturer focused on formulations for regulated markets including North America, the UK, Europe, and Australia. The company operates manufacturing facilities and supplies over-the-counter and prescription generic products across these geographies. It is listed on both BSE (scrip code 524404) and NSE.
Announcement in Detail
The transcript was filed under Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The call was moderated by Nitin Agarwal of DAM Capital Advisors and featured Founder, Chairman and Managing Director Mark Saldanha and CFO Jitendra Sharma.
North America contributed INR377 crores (approximately 45% of consolidated revenue), up 15.1% year-on-year. Australia and New Zealand delivered INR88 crores, up 53.7% year-on-year. Gross profit stood at INR497.3 crores, with gross margin improving 138 basis points year-on-year to 59.1%. Free cash flow for the quarter was INR152 crores, after net capex of INR33 crores. R&D spend was INR23.2 crores, or 2.8% of consolidated revenue. The acquisition of ABCnow GmbH, Germany, was completed with consolidation commencing from Q2 FY27.
Impact on Investors
The filing shows that QliniQ B.V. contributed approximately INR44 crores to Q1 FY27 revenue, with management indicating on the call that QliniQ is expected to generate INR150 crores to INR175 crores for the full year. Shareholders will observe that the working capital cycle improved to approximately 132 days from approximately 159 days in Q1 FY26.
Investors will note that management indicated gross margins of around 55% to 56% may be more representative going forward, compared with the 59.1% recorded in Q1 FY27, which was supported by lower-cost inventory holdings. The disclosed terms indicate that the second European acquisition, ABCnow GmbH, will begin contributing to consolidated financials only from Q2 FY27.
Sector / Market Context
India's pharmaceutical exports have remained a key growth driver, with the Pharmaceuticals Export Promotion Council of India (Pharmexcil) reporting consistent expansion in formulation exports to regulated markets. Generics demand in the UK and Europe has been supported by government-led cost-containment policies, providing a structural backdrop for Indian pharmaceutical companies expanding their front-end presence in these markets.